As everybody reading this article undoubtedly knows by now, Sanofi gave notice last Monday that it was terminating its licensing agreement with MannKind , relinquishing all rights to market Afrezza. Although the speculation about this possibility started circulating very soon after the inhaled insulin was launched, fanned by the small biotech's various vocal detractors, many true believers in the drug, certainly including myself, were stunned by the news, with the stock losing almost half of its already depressed value.